Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$57.88T
24h Vol:
$10.25B
Dominance:
MSFT:5.17%
Stocklytics Platform
BETA
Instrument logo  BRTX

BioRestorative Therapies, Inc.

BRTX
70 / 100
High Value
Penny Stock
$1.44arrow_drop_down-3.35%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$1.50
Prev. Close$1.49
EPS-4.03
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap9441964.80
PE Ratio-
LOWHIGH
Day Range1.40
1.50
52 Week Range1.20
7.13
Ratios
P/B Ratio0.76
Revenue-
Operating M. %-10,112.19%
Earnings$0.00
Earnings Growth %13.83%
EBITDA Margin %-
ROE %-106.86%
EPS-4.03

Score Breakdown

70vs 52. Market Avg.

All Score 70 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

BRTXMARKET
Value7939
Quality5840
Ownership1519
Growth5445
Dividends-38
check_circle

BioRestorative Therapies, Inc.'s Price discount from all time high of 100% is great compared to market average of 40.92%. This indicates BRTX could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$755.55
24H (%)arrow_drop_down-3.38%
24H ($)-$26.51
MARKET CAP$716.96B
PRICE$520.65
24H (%)arrow_drop_down-0.17%
24H ($)-$0.89
MARKET CAP$481.47B
PRICE$157.74
24H (%)arrow_drop_up0.76%
24H ($)$1.19
MARKET CAP$379.95B
PRICE$128.03
24H (%)arrow_drop_up0.19%
24H ($)$0.24
MARKET CAP$324.45B

About BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lance Alstodt
Headquarters
Melville
Employees
10
Exchange
NASDAQ
add BioRestorative Therapies, Inc. to watchlist

Keep an eye on BioRestorative Therapies, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is BioRestorative Therapies, Inc.'s (BRTX) price per share?

The current price per share for BioRestorative Therapies, Inc. (BRTX) is $1.46. The stock has seen a price change of -$0.03 recently, indicating a -2.01% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for BioRestorative Therapies, Inc. (BRTX)?

For BioRestorative Therapies, Inc. (BRTX), the 52-week high is $7.13, which is 388.36% from the current price. The 52-week low is $1.2, the current price is 21.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is BioRestorative Therapies, Inc. (BRTX) a growth stock?

BioRestorative Therapies, Inc. (BRTX) has shown an average price growth of -61.26% over the past three years. It has received a score of -5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying BioRestorative Therapies, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is BioRestorative Therapies, Inc. (BRTX) stock price performance year to date (YTD)?

As of the latest data, BioRestorative Therapies, Inc. (BRTX) has a year-to-date price change of -15.12%. Over the past month, the stock has experienced a price change of -8.75%. Over the last three months, the change has been -19.78%. Over the past six months, the figure is -41.37%.

question_mark
Is BioRestorative Therapies, Inc. (BRTX) a profitable company?

BioRestorative Therapies, Inc. (BRTX) has a net income of -$15.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.11K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 8.68%, providing insight into the company's sales performance and growth. Operating income is noted at -$16.5M. Furthermore, the EBITDA is -$16.53M.

question_mark
What is the market capitalization of BioRestorative Therapies, Inc. (BRTX)?

BioRestorative Therapies, Inc. (BRTX) has a market capitalization of $9.57M. The average daily trading volume is 663.87K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.